PEC

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Retrieved on: 
Monday, December 19, 2022
Dementia, Agitation, Dexmedetomidine, Therapy, Research, III, PEC, Artificial intelligence, Thought disorder, Patient, Safety, FDA, Schizophrenia, AD, Nursing, Pharmaceutical industry, Neuroscience

NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the first patient has been dosed in the pivotal Phase 3 TRANQUILITY III trial of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, orally dissolving film, under investigation for the acute treatment of agitation in patients with Alzheimer’s disease (AD). AD is the most prevalent type of dementia in the U.S.5 The TRANQUILITY program includes two investigational studies, TRANQUILITY II and TRANQUILITY III, which are designed to evaluate the safety and efficacy of BXCL501 for the acute treatment of Alzheimer’s-associated agitation in adults 65 years and older in assisted living or residential care facilities and nursing homes.

Key Points: 
  • “The prevalence of Alzheimer’s disease is unfortunately increasing and there remains no FDA-approved product indicated for patients experiencing agitation associated with this condition,” said Robert Risinger, M.D., Chief Medical Officer, Neuroscience of BioXcel Therapeutics.
  • This potential opportunity is in addition to the current acute treatment of agitation associated with schizophrenia or bipolar I or II disorder market opportunity.
  • TRANQUILITY II will assess patients in assisted living or residential care facilities requiring minimal assistance with activities of daily living.
  • TRANQUILITY III will assess patients residing predominantly in nursing homes with moderate to severe dementia who require moderate or greater assistance with activities of daily living.

AgDevCo expands portfolio in Côte d'Ivoire to improve access to agricultural inputs

Retrieved on: 
Tuesday, December 20, 2022
BII, U.S. International Development Finance Corporation, DFC, AgDevCo, Investment, Seed, Food security, Agriculture, Food, PEC, Foreign direct investment, ESG, Farmer, Financial services, Central Africa

LONDON, Dec. 20, 2022 /PRNewswire/ -- AgDevCo is pleased to announce its latest investment in the agribusiness sector in Côte d'Ivoire.

Key Points: 
  • LONDON, Dec. 20, 2022 /PRNewswire/ -- AgDevCo is pleased to announce its latest investment in the agribusiness sector in Côte d'Ivoire.
  • Afrique Phyto Plus was founded in 2013 in Côte d'Ivoire by Mohamed Hamza, Romarick Olomon and Stephane Apoque, three local entrepreneurs.
  • The group specialises in the import, distribution and mixing of crop protection products, both conventional and organic, and the distribution of seeds.
  • It is also promoting precision farming through its subsidiary Investiv', including the use of drone sprayers.

Proactive news headlines including Green Critical Minerals, Perpetual Resources, Recce Pharmaceuticals and International Graphite

Retrieved on: 
Thursday, December 15, 2022
Titan, Poseidon, Hydrogen, Lithium, Well, FWS, BRK, QPM, KZIA, RCE, AGC, JRL, NSW, QIMR Berghofer Medical Research Institute, TTM, POS, JSE, Forest and Rangeland Renewable Resources Planning Act of 1974, Research, Mining, AUT, Fever Dream, AOI, Black Swan Project, Endangered Species Act of 1973, Gold, Endangered species, EA, ESA, Knowledge, Proactivity, KTA, OTCQB, TSX, Canadian Environmental Protection Act, 1999, Murdoch Children's Research Institute, Wolfpack, ORN, AAJ, Institutional review board, SureFire, ASX, INR, PEC, IP, TMR, AAU, Environmental protection, OTC, BFS, MRE, Silicon dioxide, ILA, GCM, Research institute, Aluminium, Iron ore, Pharmaceutical industry, Oil, Uranium, Rare-earth element, Leonora

Click here

Key Points: 
  • Click here
    International Graphite Ltd (ASX:IG6) has intersected fresh areas of graphite mineralisation in a drilling program investigating the previously undrilled target SDE_1 at Springdale Graphite Project in Western Australia.
  • In 2020, Proactive featured in 809 million search results, our content was viewed over 165 million times and our readers spent over 10 million hours on our websites.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected].

Lion Electric Announces Launch of Overnight Marketed Public Offering of Units

Retrieved on: 
Monday, December 12, 2022
Quality of life, LEV, Mirabel, Quebec, NYSE, Warrant, Offering, Sale, Underwriting, Toronto Stock Exchange, Lion, News, EDGAR, Suite, Risk, Environment, Telephone, Perception, Transport, SEDAR, PEC, Lion Electric Company, TSX, National Bank of Canada, Form, Security (finance), Unit

MONTREAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- The Lion Electric Company (NYSE: LEV) (TSX: LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, today announced the launch of a marketed public offering of units (the "Units") in the United States and Canada (the "Offering").

Key Points: 
  • MONTREAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- The Lion Electric Company (NYSE: LEV) (TSX: LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, today announced the launch of a marketed public offering of units (the "Units") in the United States and Canada (the "Offering").
  • B. Riley Securities, Inc. and National Bank Financial Inc. are acting as joint bookrunners for the Offering (the "Underwriters").
  • The Offering will be priced in the context of the market with the price, total size and other final terms of the Offering to be determined at the time of entering into an underwriting agreement for the Offering.
  • Readers cannot be assured that the Offering discussed above will be completed on the terms described above, or at all.

Survey funded by ALCS shows a profession struggling to sustain itself

Retrieved on: 
Tuesday, December 6, 2022
School, Altruism, AHRC, Economic and Social Research Council, Russell Group, GVA, Publishing, Policy, University of Glasgow School of Law, Engineering and Physical Sciences Research Council, Creativity, European Parliament, Outline of physical science, Copyright, Book, PEC, Intellectual property, European, Business, ESRC, Research, Framework Programmes for Research and Technological Development, University, ALCS, Create, Kingdom, Author, EPSRC, AV, Growth, Social Sciences and Humanities Research Council, Health, Economy, Creative industries, Tourism, Engineering

LONDON, Dec. 6, 2022 /PRNewswire/ --

Key Points: 
  • Writing as a career too is one that many aspire to, but while it may be perceived to be well-paid, the latest in a series of authors' earnings surveys funded by the Authors' Licensing & Collecting Society (ALCS), shows a profession struggling to sustain itself.
  • The researchers observe that, "Such 'intrinsic motivation' may be linked to the devaluing of creative labour, and perhaps untenable market conditions."
  • The alternative, as the report suggests, leads to a diminished profession unable to sustain the vital contribution that writers make to society and our economy."
  • The Authors' Licensing and Collecting Society (ALCS) is a not-for-profit organisation started by writers for the benefit of all types of writers.

Proactive news headlines including AuKing Mining, Maximus Resources, Antilles Gold and Chase Mining Corporation

Retrieved on: 
Thursday, December 1, 2022
Well, Lithium, Poseidon, Marketing, AAU, AOI, Black Swan Project, DUN, Lead, Metal, Lamboo Gunian Community, CSG, OTC, Threadfin, AIM, ASX, Wolfpack, Kitty (terminal emulator), KZIA, Ministry, Democratic republic, DSF Refractories & Minerals Ltd, Zinc, MRE, Growth, Copper, CML, Congo, POS, OTCQB, AusIndustry, MEK, GGP, MXR, GCM, Tin, Gold, PEC, Proactivity, Cancer, Anadarko Basin, Mining, Oil, Renewable energy, Sales, Science

Click here

Key Points: 
  • Click here
    Antilles Gold Ltd (ASX:AAU, OTCQB:ANTMF) has delivered high-grade gold results including 53.5 metres at 11 g/t from 12 metres in a drill program at the outcropping gold domain of the El Pilar oxide deposit in central Cuba.
  • Click here
    Chase Mining Corporation Ltd (ASX:CML) shares rose after receiving an update from Green Critical Minerals Pty Ltd (GCM) on the Threadfin prospect within the McIntosh Graphite Project in Western Australia.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Performance Elastomers Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Growth, Oxygen, Tosoh, Rubber industry in Malaysia, Solvay S.A., Building & Construction Trades Council v. Associated Builders & Contractors of Massachusetts/Rhode Island, Inc., Electronics, Organization, Lubricant, Car, Carbon footprint, Bachelor of Engineering, Sustainability, Pierre Samuel du Pont de Nemours, Plastic, Transport, Elastomer, Lanxess, Dow Corning, USD, EV, ExxonMobil, Silicone, PEC, Health, European Automobile Manufacturers Association, Carbon, Hydrogen, Motor vehicle, Polymer, 3M, Dow, Mitsui Chemicals, Hardness, LGBT slang, Acquisition, Wacker Chemie, Speciality chemicals, Vulcanization, Lubrizol

The main types of performance elastomers are nitrile-based elastomers, fluoroelastomers, and silicone elastomers.Nitrile-based elastomers refer to emulsion polymers produced by using rubber polymerization techniques.

Key Points: 
  • The main types of performance elastomers are nitrile-based elastomers, fluoroelastomers, and silicone elastomers.Nitrile-based elastomers refer to emulsion polymers produced by using rubber polymerization techniques.
  • The regions covered in the performance elastomers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Therefore, increasing vehicle production has led to a boost in performance elastomers use, thus driving the performance elastomers market.
  • The performance elastomers market research report is one of a series of new reports that provides performance elastomers market statistics, including performance elastomers industry global market size, regional shares, competitors with an performance elastomers market share, detailed performance elastomers market segments, market trends and opportunities, and any further data you may need to thrive in the performance elastomers industry.

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

Retrieved on: 
Wednesday, November 30, 2022
Dexmedetomidine, Growth, Marketing, Trauma, Schizophrenia, Dementia, Bipolar II disorder, Food, Bipolar disorder, Agitation, Artificial intelligence, Therapy, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bipolar, Sleep, Drug Quality and Security Act, Coercion, Drug development, PEC, Breakthrough therapy, Aggression, Prostate cancer, Failure, II, Drug discovery, Algorithm, Safety, Thought disorder, Pharmaceutical industry, Neuroscience

NEW HAVEN, Conn., Nov. 30, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, orally dissolving film, for agitation associated with bipolar I or II disorder or schizophrenia.

Key Points: 
  • We anticipate top-line data from SERENITY III as well as our TRANQUILITY II trial for Alzheimers-related agitation in the first half of 2023.
  • SERENITY III is a two-part, double-blinded, placebo-controlled pivotal study designed to evaluate BXCL501 60mcg dose for at-home use.
  • SERENITY III will utilize many of the same investigators and clinical sites as SERENITY I and II.
  • BXCL501 is under investigation for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting, for the acute treatment of Alzheimers-related agitation, and as an adjunctive treatment for major depressive disorder.

Proactive news headlines including Galileo Mining, Cipherpoint, Alligator Energy and Azure Minerals

Retrieved on: 
Wednesday, November 23, 2022
Lithium, Well, LPI, Lead, Research, CCZ, Ranger, LON, ASX, Research report, Ridge, CPH, RAD, DSF Refractories & Minerals Ltd, EMD, BHA, GAL, Western Australian Government Railways, OTCQB, Rhodium, Excite, Acquisition, Tourism, HRZ, AAJ, PEC, Uranium, Proactivity, BSSP, Rubidium, Iron ore, Mining, Oil, Callisto, Science

Click here

Key Points: 
  • Click here
    Alligator Energy Ltd (ASX:AGE) has opened higher on uncovering its highest-grade uranium to date thanks to resource drilling at the Samphire Uranium Projects Blackbush deposit in South Australia.
  • Click here
    Radiopharm Theranostics Ltd (ASX:RAD) has welcomed additional data from a Phase 2a imaging trial linked to the F-18 Pivalate (RAD 101) treatment candidate.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Pharmaessentia to Host Investor Day in New York City on November 30, 2022

Retrieved on: 
Monday, November 21, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, 101 Park Avenue, Hematology, Biotechnology, Learning Technology Partners, Interferon alfa-2b, MD Anderson Cancer Center, Polycythemia, Pancreatic serous cystadenoma, Q&A, PEC, MPN, Hospital, Park Avenue, Dana–Farber Cancer Institute, PV, Fine chemical, Brigham

PharmaEssentia USA Corporation (PEC USA) , a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that it will host an Investor Day on Wednesday, November 30, 2022, 8:00 - 10:30 a.m.

Key Points: 
  • PharmaEssentia USA Corporation (PEC USA) , a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that it will host an Investor Day on Wednesday, November 30, 2022, 8:00 - 10:30 a.m.
  • ET, at Convene (101 Park Avenue) in New York City.
  • The event will include a detailed discussion on the impact of BESREMi (ropeginterferon alfa-2b-njft) in polycythemia vera (PV), its market opportunity and the Company's future-focused scientific strategy.
  • A live webcast and replay of the event will be available on the PharmaEssentia USA website at https://us.pharmaessentia.com/ .